J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARM BSE: JBCHEPHARM
NSE
1,975.30
-13.60 (-0.68%)
Prev Close
1988.9
Open Price
1982
Volume
117,063
Today Low / High
1968.3 / 1998.5
52 WK Low / High
1385.75 / 2008
Range
1,877 - 2,074
BSE
1,980.75
-7.50 (-0.38%)
Prev Close
1988.25
Open Price
1980
Volume
2,826
Today Low / High
1967.05 / 1997.95
52 WK Low / High
1303 / 2007.5
Range
1,882 - 2,080
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1975.30005 (target range: 1,877 - 2,074), reflecting a change of -13.59995 (-0.68379%). On the BSE, it is listed at 1980.75 (target range: 1,882 - 2,080), showing a change of -7.5 (-0.37722%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
18 Feb
1,982.00
-0.40%
17 Feb
1,989.00
-0.01%
16 Feb
1,905.20
3.86%
13 Feb
1,890.00
0.10%
12 Feb
1,894.80
0.81%
11 Feb
1,916.90
-1.15%
10 Feb
1,897.50
1.35%
09 Feb
1,857.50
1.36%
06 Feb
1,844.00
0.30%
05 Feb
1,877.40
-1.05%
04 Feb
1,900.10
-0.37%
03 Feb
1,909.40
-0.72%
02 Feb
1,875.00
-0.55%
01 Feb
1,877.20
-0.08%
30 Jan
1,830.00
2.16%
29 Jan
1,856.30
-0.55%
28 Jan
1,890.00
-1.78%
27 Jan
1,846.10
1.70%
23 Jan
1,907.00
-3.20%
22 Jan
1,896.00
0.30%
21 Jan
1,861.00
1.27%
J. B. Chemicals & Pharmaceuticals Limited Graph
J. B. Chemicals & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for J. B. Chemicals & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,975.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,980.75 | 2,000.56 | 1,800.50 - 2,200.61 |
| 2,020.37 | 1,616.29 - 2,424.44 | ||
| 2,040.17 | 1,428.12 - 2,652.22 | ||
| Bearish Scenario | 1,980.75 | 1,960.94 | 1,764.85 - 2,157.04 |
| 1,941.14 | 1,552.91 - 2,329.36 | ||
| 1,921.33 | 1,344.93 - 2,497.73 |
Overview of J. B. Chemicals & Pharmaceuticals Limited
ISIN
INE572A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
191,855
Market Cap
316,897,428,559
Last Dividend
19.7
Official Website
IPO Date
2002-07-01
DCF Diff
-1,860.06
DCF
3,849
Financial Ratios Every Investor Needs
Stock Dividend of JBCHEPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-11 | February 11, 26 | 12.7 | 12.7 | 2026-02-11 | 2026-02-25 | |
| 2025-07-30 | July 30, 25 | 7 | 7 | 2025-07-30 | 2025-08-13 | |
| 2025-02-07 | February 07, 25 | 8.5 | 8.5 | 2025-02-08 | 2025-02-21 | |
| 2024-08-14 | August 14, 24 | 6.75 | 6.75 | 2024-08-14 | 2024-09-20 | |
| 2024-02-16 | February 16, 24 | 5.5 | 5.5 | 2024-02-16 | 2024-03-07 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,917.99 Cr | 1,316.55 Cr | 2,601.44 Cr | 0.6640 | 44.84 Cr | 36.25 Cr | 1,913.83 Cr | 659.58 Cr | 42.45 | 1,031.84 Cr | 0.1683 |
| 2024-03-31 | 3,484.18 Cr | 2,121.75 Cr | 1,345.88 Cr | 0.3863 | 30.56 Cr | 603.43 Cr | 754.16 Cr | 552.63 Cr | 35.66 | 933.48 Cr | 0.1586 |
| 2023-03-31 | 3,116.51 Cr | 2,015.49 Cr | 1,114.44 Cr | 0.3576 | 31.93 Cr | 547.04 Cr | 584.51 Cr | 409.84 Cr | 26.50 | 704.37 Cr | 0.1315 |
| 2022-03-31 | 2,424.24 Cr | 863.37 Cr | 1,560.87 Cr | 0.6439 | 29.11 Cr | 441.28 Cr | 460.48 Cr | 385.36 Cr | 24.93 | 581.53 Cr | 0.1590 |
| 2021-03-31 | 2,005.85 Cr | 717.44 Cr | 1,288.41 Cr | 0.6423 | 23.53 Cr | 341.95 Cr | 455.67 Cr | 447.96 Cr | 28.98 | 672.26 Cr | 0.2233 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 129.45 Cr | 4,273.78 Cr | 840.46 Cr | 3,433.3200 Cr | 27.89 Cr | -101.56 Cr | 528.95 Cr | 656.64 Cr | 10.32 Cr | 1.90 Cr | 27.98 Cr | 632.3300 Cr |
| 2024-03-31 | 88.22 Cr | 3,994.13 Cr | 1,070.80 Cr | 2,923.3300 Cr | 377.66 Cr | 289.44 Cr | 502.51 Cr | 634.88 Cr | 12.99 Cr | 1.70 Cr | 29.09 Cr | 868.2261 Cr |
| 2023-03-31 | 76.93 Cr | 3,553.87 Cr | 1,073.52 Cr | 2,480.3500 Cr | 572.45 Cr | 495.52 Cr | 430.49 Cr | 576.42 Cr | 118.25 Cr | 2.49 Cr | 28.09 Cr | 554.4500 Cr |
| 2022-03-31 | 56.54 Cr | 2,607.40 Cr | 468.79 Cr | 2,134.1230 Cr | 54.56 Cr | -1.99 Cr | 409.96 Cr | 566.82 Cr | 116.47 Cr | 3.17 Cr | 12.72 Cr | 383.7156 Cr |
| 2021-03-31 | 28.69 Cr | 2,238.12 Cr | 424.69 Cr | 1,809.7248 Cr | 44.99 Cr | 16.30 Cr | 347.45 Cr | 569.66 Cr | 108.56 Cr | 4.93 Cr | -651.88 Cr | 345.2737 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 902.4500 Cr | -295.8900 Cr | -579.6800 Cr | 804.8600 Cr | 26.8700 Cr | 115.0900 Cr | -97.5900 Cr | 659.5800 Cr | -343.9200 Cr | -237.0400 Cr | -26.4400 Cr |
| 2024-03-31 | 800.6117 Cr | -407.9074 Cr | -341.2720 Cr | 539.2447 Cr | 11.0507 Cr | 88.2151 Cr | -126.1128 Cr | 552.6278 Cr | -191.5957 Cr | -156.9875 Cr | -72.0300 Cr |
| 2023-03-31 | 625.6100 Cr | -961.7900 Cr | 356.5400 Cr | -139.3400 Cr | 20.3900 Cr | 76.9300 Cr | -764.9500 Cr | 555.2300 Cr | 523.1596 Cr | -127.5926 Cr | -20.5200 Cr |
| 2022-03-31 | 170.1345 Cr | 2.3199 Cr | -138.3851 Cr | -536.6547 Cr | 34.0703 Cr | 56.5441 Cr | -706.7892 Cr | 504.9020 Cr | -0.3273 Cr | -127.5628 Cr | -62.5143 Cr |
| 2021-03-31 | 314.7849 Cr | -230.6758 Cr | -87.4228 Cr | 267.0119 Cr | -3.2782 Cr | 22.4737 Cr | -47.7730 Cr | 596.8854 Cr | 0.3223 Cr | -73.2403 Cr | -70.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,064.72 Cr | 566.20 Cr | 498.52 Cr | 0.4682 | 250.47 Cr | 197.89 Cr | 12.63 | 314.10 Cr | 0.1859 |
| 2025-09-30 | 1,084.90 Cr | 345.49 Cr | 739.41 Cr | 0.6815 | 265.16 Cr | 207.82 Cr | 13.29 | 324.94 Cr | 0.1916 |
| 2025-06-30 | 1,093.94 Cr | 584.09 Cr | 509.85 Cr | 0.4661 | 258.17 Cr | 202.38 Cr | 12.97 | 315.42 Cr | 0.1850 |
| 2025-03-31 | 949.48 Cr | 321.64 Cr | 627.84 Cr | 0.6612 | 1,233.03 Cr | 145.69 Cr | 9.36 | 222.76 Cr | 0.1534 |
| 2024-12-31 | 963.49 Cr | 316.74 Cr | 646.75 Cr | 0.6713 | 212.57 Cr | 162.49 Cr | 10.46 | 262.51 Cr | 0.1686 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 93.78 Cr | 807.60 Cr | 901.38 Cr | 938.32 Cr | 576.58 Cr | 2,555.13 Cr | 678.66 Cr | 4,712.40 Cr | 906.66 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 450.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,433.32 Cr |
| 2025-03-31 | 129.45 Cr | 335.00 Cr | 446.56 Cr | 815.38 Cr | 528.95 Cr | 1,922.74 Cr | 656.64 Cr | 4,273.78 Cr | 840.46 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 416.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,212.23 Cr |
| 2024-09-30 | 97.46 Cr | 319.40 Cr | 416.86 Cr | 817.14 Cr | 543.67 Cr | 1,913.30 Cr | 641.67 Cr | 4,029.41 Cr | 817.18 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 202.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 145.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 162.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 174.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 176.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-09-18 | September 18, 23 | 2:1 |
| 2005-04-05 | April 05, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,724.60 | ₹4,137,893,089,262.00 | ₹911,079.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,270.50 | ₹1,664,620,730,890.00 | ₹338,163.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,193.30 | ₹1,419,203,195,863.00 | ₹188,122.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,281.60 | ₹1,067,019,392,304.00 | ₹407,717.00 |
| Lupin Limited | LUPIN | ₹2,240.00 | ₹1,023,608,199,040.00 | ₹228,109.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.70 | ₹912,352,358,733.00 | ₹170,075.00 |
| Mankind Pharma Limited | MANKIND | ₹2,062.50 | ₹851,410,461,000.00 | ₹144,216.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.20 | ₹672,684,439,759.00 | ₹2,579,360.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,445.00 | ₹651,031,425,000.00 | ₹47,019.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,018.80 | ₹569,706,993,209.00 | ₹246,677.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,030.05 | ₹556,079,272,289.00 | ₹836,625.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,490.00 | ₹378,019,284,820.00 | ₹42,781.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,968.10 | ₹370,821,438,088.00 | ₹27,322.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,975.30 | ₹317,090,069,640.00 | ₹117,063.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,465.80 | ₹277,875,429,132.00 | ₹34,919.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,417.00 | ₹230,251,403,473.00 | ₹328,620.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,890.50 | ₹222,262,500,000.00 | ₹2,123.00 |
| Eris Lifesciences Limited | ERIS | ₹1,340.80 | ₹182,639,607,453.00 | ₹16,240.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,650.00 | ₹175,127,984,850.00 | ₹33,770.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹894.10 | ₹160,142,134,767.00 | ₹772,295.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹773.60 | ₹152,061,232,726.00 | ₹21,134.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹895.90 | ₹141,883,457,233.00 | ₹54,611.00 |
| Granules India Limited | GRANULES | ₹578.65 | ₹140,420,252,513.00 | ₹707,480.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,710.10 | ₹129,987,601,330.00 | ₹65,764.00 |
| Cohance Lifesciences Limited | COHANCE | ₹324.85 | ₹124,276,935,429.00 | ₹7,643,641.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹899.45 | ₹110,394,895,200.00 | ₹12,821.00 |
| Viyash Scientific Limited | VIYASH | ₹224.48 | ₹97,919,423,884.00 | ₹421,442.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,025.00 | ₹83,411,894,550.00 | ₹5,019.00 |
| Strides Pharma Science Limited | STAR | ₹884.40 | ₹81,517,548,262.00 | ₹250,558.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹487.65 | ₹74,660,218,584.00 | ₹340,533.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹723.65 | ₹65,596,911,409.00 | ₹69,231.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹329.00 | ₹64,346,417,464.00 | ₹98,681.00 |
| FDC Limited | FDC | ₹381.25 | ₹62,071,344,525.00 | ₹42,347.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.97 | ₹43,151,635,556.00 | ₹183,933.00 |
| Innova Captab Limited | INNOVACAP | ₹676.05 | ₹38,686,913,250.00 | ₹9,816.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹335.15 | ₹36,519,708,565.00 | ₹298,755.00 |
| Suven Life Sciences Limited | SUVEN | ₹152.31 | ₹34,646,564,940.00 | ₹105,233.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹375.05 | ₹34,230,813,500.00 | ₹56,150.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹668.65 | ₹33,913,330,573.00 | ₹11,144.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,985.90 | ₹32,844,829,889.00 | ₹2,160.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹294.00 | ₹29,483,056,764.00 | ₹14,553.00 |
Key Executives
Head of Representative Office - Tashkent & Uzbekistan
Alisher Djabbarov
Gender: Not Specified
Year Born:
Vice President of Finance & Accounts
Bhagwat Singh Deora
Gender: male
Year Born: 1982
Vice President of Legal
Himanshu Ranvah
Gender: male
Year Born: 1985
President of Operations
Kunal Khanna
Gender: male
Year Born: 1980
Chief Financial Officer
Narayan Saraf
Gender: male
Year Born: 1980
Chief Executive Officer & Whole-Time Director
Nikhil Ashokkumar Chopra
Gender: male
Year Born: 1973
Executive Vice President of Operations of Daman
Parmeshwar Bang
Gender: male
Year Born: 1968
President of Global Business
Pradeep Kumar Singh
Gender: male
Year Born: 1964
Vice President of Secretarial & Company Secretary and Compliance Officer
Sandeep Anil Phadnis
Gender: male
Year Born: 1968
Vice President of Human Resources & Administration
Sridhar Bharadwaj
Gender: male
Year Born: 1967
Vice President of Information & Technology
Suresh Bhise
Gender: male
Year Born: 1966
Assistant Vice President Human Resource
Suresh Amin
Gender: Not Specified
Year Born:
FAQs about J. B. Chemicals & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Nikhil Ashokkumar Chopra.
What is the current market price of the stock?
The current price is ₹1,974.10.
What is the 52-week price range?
The range is ₹1385.75-2008.
What is the market capitalization of the company?
The market capitalization is ₹31,689.74 crores.
What is the dividend yield?
The dividend yield is 1.00%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 41.03.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of J. B. Chemicals & Pharmaceuticals Limited (ISIN: INE572A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹31,689.74 crores and an average daily volume of 191,855 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹19.7.